Leerink Partnrs Has Negative Outlook for Revvity Q1 Earnings

Revvity, Inc. (NYSE:RVTY) – Investment analysts at Leerink Partnrs decreased their Q1 2025 EPS estimates for shares of Revvity in a report issued on Friday, November 22nd. Leerink Partnrs analyst P. Souda now anticipates that the company will earn $1.09 per share for the quarter, down from their previous forecast of $1.14. The consensus estimate for Revvity’s current full-year earnings is $4.85 per share. Leerink Partnrs also issued estimates for Revvity’s Q4 2025 earnings at $1.47 EPS.

Revvity (NYSE:RVTY) last posted its quarterly earnings results on Monday, November 4th. The company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.15. Revvity had a net margin of 9.34% and a return on equity of 7.42%. The company had revenue of $684.10 million for the quarter, compared to the consensus estimate of $679.66 million. During the same quarter last year, the firm posted $1.18 earnings per share. Revvity’s revenue was up 2.1% on a year-over-year basis.

Several other equities research analysts have also commented on the company. Citigroup upped their price target on Revvity from $135.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Robert W. Baird raised their price target on shares of Revvity from $136.00 to $138.00 and gave the company an “outperform” rating in a report on Tuesday, November 5th. Jefferies Financial Group boosted their price objective on shares of Revvity from $115.00 to $125.00 and gave the stock a “hold” rating in a research note on Monday, July 29th. Bank of America raised their target price on shares of Revvity from $118.00 to $127.00 and gave the company a “neutral” rating in a research note on Tuesday, July 30th. Finally, Barclays raised shares of Revvity from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $125.00 to $140.00 in a research report on Tuesday, October 15th. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Revvity presently has a consensus rating of “Moderate Buy” and an average price target of $132.07.

Revvity Trading Up 0.8 %

Shares of RVTY opened at $112.03 on Monday. Revvity has a twelve month low of $86.30 and a twelve month high of $129.50. The firm has a market capitalization of $13.63 billion, a P/E ratio of 54.12, a price-to-earnings-growth ratio of 2.77 and a beta of 1.05. The company has a current ratio of 3.56, a quick ratio of 2.97 and a debt-to-equity ratio of 0.40. The stock’s fifty day simple moving average is $120.53 and its 200 day simple moving average is $115.65.

Hedge Funds Weigh In On Revvity

Hedge funds have recently bought and sold shares of the company. Jane Street Group LLC lifted its position in shares of Revvity by 516.4% in the 1st quarter. Jane Street Group LLC now owns 453,343 shares of the company’s stock worth $47,601,000 after buying an additional 379,802 shares during the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Revvity by 3,171.3% during the second quarter. Assenagon Asset Management S.A. now owns 87,180 shares of the company’s stock valued at $9,142,000 after purchasing an additional 84,515 shares during the last quarter. DekaBank Deutsche Girozentrale raised its position in shares of Revvity by 27.8% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 84,383 shares of the company’s stock worth $8,790,000 after purchasing an additional 18,367 shares during the period. Virtu Financial LLC acquired a new position in Revvity during the 1st quarter valued at approximately $1,214,000. Finally, Artemis Investment Management LLP grew its stake in Revvity by 21.3% during the 2nd quarter. Artemis Investment Management LLP now owns 107,634 shares of the company’s stock worth $11,287,000 after buying an additional 18,916 shares during the last quarter. 86.65% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Revvity

In other news, insider Tajinder S. Vohra sold 2,154 shares of the business’s stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the completion of the sale, the insider now owns 19,652 shares of the company’s stock, valued at approximately $2,392,237.96. The trade was a 9.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.60% of the stock is currently owned by corporate insiders.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, January 17th. This represents a $0.28 annualized dividend and a yield of 0.25%. Revvity’s dividend payout ratio is presently 13.53%.

Revvity announced that its Board of Directors has authorized a stock buyback program on Monday, November 4th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the company to repurchase up to 6.5% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.